Novavax is participating in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that is being led by the University Hospital Southampton NHS Foundation Trust and other UK National Institute for Health Research (NIHR) sites. Novavax' recombinant protein vaccine candidate, NVX-CoV2373, is one of seven COVID-19 vaccines that will be studied to evaluate the potential for providing a booster dose from different manufacturers in people who have previously received two doses of an authorized vaccine. This study will assess the safety and immune response against COVID-19 provided by these various vaccine schedules. The study will begin during the first week of June and is receiving support from the UK government Vaccines Task Force (VTF) and Department of Health and Social Care (DHSC).
To learn more, read the DHCS press release here.